[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578221":3},{"organization":4,"armGroups":7,"interventions":55,"overallOfficials":66,"centralContacts":71,"locations":76,"responsibleParty":227,"collaborators":61,"id":229,"slug":230,"hasResults":231,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":61,"eligibilityCriteria":235,"healthyVolunteers":236,"sex":237,"minAge":238,"maxAge":239,"enrollmentInfo":240,"targetDuration":61,"studyType":243,"phases":244,"briefSummary":246,"conditions":247,"keywords":61,"overallStatus":79,"whyStopped":61,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},{"fullName":5,"class":6},"Bambusa Therapeutics","INDUSTRY",[8,14,18,22,28,32,36,40,44,47,51],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A Single Ascending Dose BBT001","EXPERIMENTAL","A single dose of BBT001 will be administered in healthy volunteers",[13],"Drug: BBT001",{"label":15,"type":10,"description":16,"interventionNames":17},"Part B Multiple Ascending Dose BBT001","Multiple doses of BBT001 will be administered in healthy volunteers.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part C Multiple Ascending Dose BBT001","Multiple doses of BBT001 will be administered in patients with atopic dermatitis.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Part A Single Ascending Dose Placebo","PLACEBO_COMPARATOR","A single dose of Placebo will be administered in healthy volunteers",[27],"Drug: Placebo",{"label":29,"type":24,"description":30,"interventionNames":31},"Part B Multiple Ascending Dose Placebo","Multiple doses of Placebo will be administered in healthy volunteers.",[27],{"label":33,"type":24,"description":34,"interventionNames":35},"Part C Multiple Ascending Dose Placebo","Multiple doses of Placebo will be administered in patients with atopic dermatitis.",[27],{"label":37,"type":38,"description":11,"interventionNames":39},"Part D Single Ascending Dose BBT001","ACTIVE_COMPARATOR",[13],{"label":41,"type":24,"description":42,"interventionNames":43},"Part D Single Ascending Dose Placebo","A single dose of placebo will be administered in healthy volunteers",[27],{"label":45,"type":38,"description":20,"interventionNames":46},"Part E Multiple Ascending Dose BBT001 - Dose Level 1",[13],{"label":48,"type":24,"description":49,"interventionNames":50},"Part E Multiple Ascending Dose Placebo","Multiple doses of placebo will be administered in patients with atopic dermatitis.",[27],{"label":52,"type":38,"description":53,"interventionNames":54},"Part E Multiple Ascending Dose BBT001 - Dose Level 2","Multiple doses of BBT001 will be administered in patients with atopic dermatitis",[13],[56,62],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":61},"DRUG","BBT001","BBT001 will be administered",[9,15,19,37,45,52],null,{"type":57,"name":63,"description":64,"armGroupLabels":65,"otherNames":61},"Placebo","Placebo will be administered",[23,29,33,41,48],[67],{"name":68,"affiliation":69,"role":70},"Lisa Li","Bambusa Therapeutics, Inc.","STUDY_DIRECTOR",[72],{"name":68,"role":73,"phone":74,"phoneExt":61,"email":75},"CONTACT","+1 617-848-6188","Lisa.Li@bambusatx.com",[77,91,100,109,122,132,147,157,169,177,189,200,209,218],{"facility":78,"status":79,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":61},"First OC Dermatology","RECRUITING","Irvine","California","92614","United States","US",{"type":86,"coordinates":87},"Point",[88,89],-117.82311,33.66946,{"lat":89,"lon":88},{"facility":92,"status":79,"city":93,"state":93,"zip":94,"country":83,"countryCode":84,"cosmosGeoPoint":95,"geoPoint":99,"contacts":61},"OptiSkin Medical","New York","10128",{"type":86,"coordinates":96},[97,98],-74.00597,40.71427,{"lat":98,"lon":97},{"facility":101,"status":79,"city":102,"state":93,"zip":103,"country":83,"countryCode":84,"cosmosGeoPoint":104,"geoPoint":108,"contacts":61},"Equity Medical, LLC","The Bronx","10455",{"type":86,"coordinates":105},[106,107],-73.86641,40.84985,{"lat":107,"lon":106},{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":121,"contacts":61},"Fremantle Dermatology","NOT_YET_RECRUITING","Fremantle","Western Australia","6160","Australia","AU",{"type":86,"coordinates":118},[119,120],115.74557,-32.05632,{"lat":120,"lon":119},{"facility":123,"status":124,"city":125,"state":113,"zip":126,"country":115,"countryCode":116,"cosmosGeoPoint":127,"geoPoint":131,"contacts":61},"Linear Clinical Research","COMPLETED","Perth","6009",{"type":86,"coordinates":128},[129,130],115.8614,-31.95224,{"lat":130,"lon":129},{"facility":133,"status":79,"city":134,"state":135,"zip":136,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Optimal Clinical Trials Central Auckland","Grafton","Auckland","1010","New Zealand","NZ",{"type":86,"coordinates":140},[141,142],174.76566,-36.86029,{"lat":142,"lon":141},[145],{"name":146,"role":73,"phone":61,"phoneExt":61,"email":61},"Arna Letica",{"facility":148,"status":149,"city":150,"state":135,"zip":151,"country":137,"countryCode":138,"cosmosGeoPoint":152,"geoPoint":156,"contacts":61},"Aotearoa Clinical Trials","WITHDRAWN","Otahuhu","2025",{"type":86,"coordinates":153},[154,155],174.84019,-36.9382,{"lat":155,"lon":154},{"facility":158,"status":79,"city":159,"state":135,"zip":160,"country":137,"countryCode":138,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Pacific Clinical Research Network (PCRN) - Auckland","Takapuna","0622",{"type":86,"coordinates":162},[163,164],174.77583,-36.79167,{"lat":164,"lon":163},[167],{"name":168,"role":73,"phone":61,"phoneExt":61,"email":61},"Paul Hamilton",{"facility":170,"status":79,"city":171,"state":61,"zip":61,"country":137,"countryCode":138,"cosmosGeoPoint":172,"geoPoint":176,"contacts":61},"Optimal Clinical Trials Ltd - Christchurch","Christchurch",{"type":86,"coordinates":173},[174,175],172.63333,-43.53333,{"lat":175,"lon":174},{"facility":178,"status":79,"city":179,"state":61,"zip":180,"country":137,"countryCode":138,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Pacific Clinical Research Network (PCRN) Wellington","Upper Hutt","5018",{"type":86,"coordinates":182},[183,184],175.0502,-41.13827,{"lat":184,"lon":183},[187],{"name":188,"role":73,"phone":61,"phoneExt":61,"email":61},"Tim Humphrey",{"facility":190,"status":79,"city":191,"state":61,"zip":192,"country":193,"countryCode":194,"cosmosGeoPoint":195,"geoPoint":199,"contacts":61},"Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi","Lodz","91-347","Poland","PL",{"type":86,"coordinates":196},[197,198],19.47395,51.77058,{"lat":198,"lon":197},{"facility":201,"status":79,"city":202,"state":61,"zip":203,"country":193,"countryCode":194,"cosmosGeoPoint":204,"geoPoint":208,"contacts":61},"Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie","Rzeszów","35-055",{"type":86,"coordinates":205},[206,207],21.99901,50.04132,{"lat":207,"lon":206},{"facility":210,"status":79,"city":211,"state":61,"zip":212,"country":193,"countryCode":194,"cosmosGeoPoint":213,"geoPoint":217,"contacts":61},"Państwowy Instytut Medyczny MSWiA","Warsaw","02-507",{"type":86,"coordinates":214},[215,216],21.01178,52.22977,{"lat":216,"lon":215},{"facility":219,"status":79,"city":220,"state":61,"zip":221,"country":193,"countryCode":194,"cosmosGeoPoint":222,"geoPoint":226,"contacts":61},"Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska","Wroclaw","50-566",{"type":86,"coordinates":223},[224,225],17.03006,51.10286,{"lat":225,"lon":224},{"type":228,"investigatorFullName":61,"investigatorTitle":61,"investigatorAffiliation":61,"oldNameTitle":61,"oldOrganization":61},"SPONSOR","100578221","phase-1-a-study-of-bbt001-in-healthy-volunteers-hvs-and-in-adult-patients-with-atopic-dermatitis-ad-100578221",false,"NCT06808477","A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)","A Randomized, Blinded, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 in HVs and Adult Patients With AD","Key Inclusion Criteria\n\n1. Negative pregnancy tests for women of childbearing potential.\n2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.\n3. Non-smokers, healthy current smokers (≤5 cigarettes\u002Fday), or ex-smokers.\n4. Adequate contraception use (for men and women of childbearing potential).\n\nKey Inclusion Criteria (Parts A, B, and D)\n\n1. Age of 18-65 years.\n2. Body mass index of 18 to 32 kg\u002Fm², weight capped at 120 kg.\n3. No clinically significant abnormalities or history of relevant diseases.\n\nKey Inclusion Criteria (Parts C and E only)\n\n1. Age of 18-72 years.\n2. Body mass index ≥16 kg\u002Fm², weight capped at 125 kg.\n3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.\n4. Moderate to severe atopic dermatitis\n5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3\n6. Atopic lesions cover ≥10% of body surface area (BSA)\n7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.\n\nKey Exclusion Criteria\n\n1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.\n2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.\n3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.\n4. Positive drug\u002Falcohol tests or abnormal vital signs at screening or Day -1.\n5. Abnormal Electrocardiogram (ECG) findings\n6. History of drug\u002Falcohol abuse in the past 2 years.\n7. Donated \\>500mL blood within 2 months of screening.\n8. History of severe allergic reactions or hypersensitivity.\n\nKey Exclusion Criteria (Parts A, B, and D only)\n\n1\\. History of atopic dermatitis\n\nKey Exclusion Criteria (Parts C and E only)\n\n1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.\n2. Receipt of immunoglobulin or blood products within 30 days.\n3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.\n4. Chronic pruritus from conditions other than atopic dermatitis.\n5. Acute\u002Ftreated infections or chronic skin infections.\n6. Current use of sedating antihistamines or corticosteroids.",true,"ALL","18 Years","72 Years",{"count":241,"type":242},237,"ESTIMATED","INTERVENTIONAL",[245],"PHASE1","This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).",[248],"Atopic Dermatitis","2026-08-12",{"date":251,"type":252},"2026-08-13","ACTUAL",{"date":254,"type":252},"2025-02-27",{"date":256,"type":242},"2027-02-28",{"name":5,"class":6},14]